Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03246971 · ClinicalTrials.gov registry record · Phase 2
Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain
A Phase 2 study of Acute Pain and Bunion, sponsored by iX Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT03246971: Completed Phase 2 study of Acute Pain and Bunion, sponsored by iX Biopharma.
NCT03246971 is a Phase 2 study of Acute Pain and Bunion that has completed, run by iX Biopharma. The registered enrollment target is 125 participants, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03246971, a Phase 2 study of Acute Pain and Bunion, has completed, sponsored by iX Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the safety and effectiveness of Wafermine™ for post-bunionectomy or post-abdominoplasty pain over a 24 hours period. For subjects undergoing bunionectomy, 2 out of 3 subjects will receive Wafermine™ and 1 out of 3 subjects will receive placebo. For subjects undergoing abdominoplasty, 3 out of 4 subjects will receive Wafermine™ and 1 out of 4 subjects will receive placebo.
Conditions Studied
Interventions
- DRUG Placebos
- DRUG Wafermine™ 50 mg
- DRUG Wafermine™ 75 mg
- DRUG Wafermine™ 25 mg
Study Locations (1)
California
- Lotus Clinical Research - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2017-08-24 |
| Est. Completion | 2018-07-17 |
| Phase | Phase 2 |
What the finished NCT03246971 record still lists
NCT03246971 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (53% lower).
The record links to 3 conditions, with Acute Pain appearing as the primary indexed condition, and to 4 interventions - of which Placebos is the first listed.
NCT03246971 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03246971 about?
NCT03246971 is a clinical study titled "Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain". This study evaluates the safety and effectiveness of Wafermine™ for post-bunionectomy or post-abdominoplasty pain over a 24 hours period. For subjects undergoing bunionectomy, 2 out of 3 subjects will receive Wafermine™ and 1 out of 3 subjects will receive placebo. For subjects undergoing abdominopl...
What is the current status of trial NCT03246971?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2017-08-24. Estimated completion is 2018-07-17.
What conditions does trial NCT03246971 study?
This clinical trial studies the following conditions: Acute Pain, Bunion, Abdominoplasty.
What interventions are being tested in trial NCT03246971?
The interventions under investigation include: Placebos (DRUG), Wafermine™ 50 mg (DRUG), Wafermine™ 75 mg (DRUG), Wafermine™ 25 mg (DRUG).
Who is sponsoring clinical trial NCT03246971?
This trial is sponsored by iX Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03246971 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03246971's enrollment target sits among peer trials
125 21st of 50 higher than 30 of 50 other Acute Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Pain From Wisdom Molar Extractions
RECRUITING · Phase 2
-
Twin Block, Pain Medications and Third Molar Extractions
RECRUITING · Phase 2
-
Liposome Bupivacaine Interscalene Total Shoulder
COMPLETED · Phase 2
-
Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
COMPLETED · Phase 2
-
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
COMPLETED · Phase 2
-
A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI